Pharma companies involved in the sale of heartburn therapy Zantac have won a key battle in litigation brought by patients who claim the drug caused them to develop cancer.
Boehringer Ingelheim has appointed Lykke Hinsch Gylvin as its new head of medicine and chief medical officer, succeeding Mehdi Shahidi, who left the position earlier this year after three y
Boehringer Ingelheim was an early adopter of Medidata's electronic data collection (EDC) platform for clinical trials, and has now extended and expanded the contract.
Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosi
German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP)
The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma compa